Herpesvirus in Idiopathic Pulmonary Fibrosis
特发性肺纤维化中的疱疹病毒
基本信息
- 批准号:6906673
- 负责人:
- 金额:$ 19.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-15 至 2007-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic, pulmonary disease with no proven effective treatment. Spontaneous remissions do not occur and death usually ensues within 3 to 5 years of diagnosis. The pathogenesis of IPF is complex and not fully delineated. However, a critical pathogenic event in the development of IPF is ongoing injury of lung epithelium. The cause of this injury remains unknown although chronic viral infection of the lungs, particularly with herpesvirus, is garnering increasing interest as a potential cause of the in jury. Studies from us and others that use lung tissue from humans with IPF show the presence of one or more herpesviruses in the lungs of IPF patients. In addition, we found that mice with a T helper(Th)-2 phenotype inoculated with murine herpesvirus develop chronic lung epithelial infection and many histologic features reminiscent of IPF. Based on these data, our concept is that herpesvirus does not normally infect the lung but in a susceptible host, herpesvirus infects lung epithelium and the infected epithelium expresses cytokines and growth factors which directs the fibrogenic response leading to the development of IPF. Our long term goal is to prove that there is a causal link between herpesvirus infection of the lung and the development of IPF. A critical step in reaching that goal is to develop strategies to eradicate herpesvirus infection in the lung and then show amelioration of IPF. The purpose of the current proposal is two-fold. First is to provide sufficient evidence for a potential role of herpesvirus in the pathogenesis of IPF to justify an antiviral therapeutic trial in IPF. Second is to gather information on the viral replication cycle in the IPF lung in order to design the most effective antiviral strategy for such a trial. Therefore, we propose the following specific aim.
In lung tissue from patients with IPF:
i. Identify which herpesviruses are present in the lung using PCR;
ii. Identify cellular sites of herpesvirus infection using immunohistochemical and immunofluorescent analysis for detection of viral proteins;
iii. Determine whether herpesviruses are primarily latent in the infected cells or whether lytic replication is occurring; and
iv. Determine whether cells infected with herpesvirus, or neighboring uninfected cells, express host proteins known to be involved in the pathogenesis of IPF.
Control lung tissue from patients with chronic lung diseases not associated with progressive fibrosis will be examined.
描述(由申请人提供):特发性肺纤维化(IPF)是一种进行性纤维化肺部疾病,目前尚无有效治疗方法。自发缓解不会发生,死亡通常在诊断后3至5年内发生。 IPF的发病机制复杂,尚未完全阐明。 然而,IPF发展中的一个关键致病事件是肺上皮的持续损伤。 这种损伤的原因仍然未知,尽管肺部的慢性病毒感染,特别是疱疹病毒感染,作为损伤的潜在原因越来越受到关注。 我们和其他使用IPF患者肺组织的研究显示,IPF患者的肺中存在一种或多种疱疹病毒。 此外,我们发现,小鼠辅助性T细胞(Th)-2表型接种鼠疱疹病毒发展慢性肺上皮感染和许多组织学特征联想到IPF。 基于这些数据,我们的概念是疱疹病毒通常不感染肺,但在易感宿主中,疱疹病毒感染肺上皮,感染的上皮表达细胞因子和生长因子,其指导导致IPF发展的纤维化反应。 我们的长期目标是证明肺疱疹病毒感染与IPF的发生之间存在因果关系。 实现这一目标的关键步骤是制定策略以根除肺部疱疹病毒感染,然后显示IPF的改善。 本提案有两个目的。 首先是提供足够的证据证明疱疹病毒在IPF发病机制中的潜在作用,以证明在IPF中进行抗病毒治疗试验的合理性。 其次是收集IPF肺中病毒复制周期的信息,以便为此类试验设计最有效的抗病毒策略。因此,我们提出以下具体目标。
在IPF患者的肺组织中:
I.使用PCR鉴定哪些疱疹病毒存在于肺中;
二.用免疫组织化学和免疫荧光分析法检测疱疹病毒蛋白,确定疱疹病毒感染的细胞部位;
三.确定疱疹病毒是否主要潜伏在受感染的细胞中或是否发生裂解性复制;和
四. 确定疱疹病毒感染的细胞或邻近未感染细胞是否表达已知参与IPF发病机制的宿主蛋白。
将检查来自患有与进行性纤维化无关的慢性肺病的患者的对照肺组织。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arlene A Stecenko其他文献
Arlene A Stecenko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arlene A Stecenko', 18)}}的其他基金
C/EBP Beta Regulation of Lung Inflammation
肺部炎症的 C/EBP Beta 调节
- 批准号:
6778762 - 财政年份:2004
- 资助金额:
$ 19.13万 - 项目类别:
C/EBP Beta Regulation of Lung Inflammation
肺部炎症的 C/EBP Beta 调节
- 批准号:
6893666 - 财政年份:2004
- 资助金额:
$ 19.13万 - 项目类别:
C/EBP Beta Regulation of Lung Inflammation
肺部炎症的 C/EBP Beta 调节
- 批准号:
7228878 - 财政年份:2004
- 资助金额:
$ 19.13万 - 项目类别:
C/EBP Beta Regulation of Lung Inflammation
肺部炎症的 C/EBP Beta 调节
- 批准号:
7057386 - 财政年份:2004
- 资助金额:
$ 19.13万 - 项目类别: